Cardio-Oncology

New AHA Cardio-Oncology Initiatives

Because the risk of death from heart disease is up to 6 times higher in cancer survivors than the general population, the AHA:

  • Announced a new Strategically Focused Research Network (SFRN) dedicated to cardio-oncology. With $15 million in funding, research awards will become available in 2020. The SFRN page will provide periodic updates.
  • Formed an alliance with CancerLinQ LLC, a nonprofit subsidiary of the American Society of Clinical Oncology, to accelerate scientific discoveries that can ultimately improve care and quality of life for cardio-oncology patients. Through efforts of the alliance, oncology datasets from the CancerLinQ Discovery® database will be made available to academic researchers, nonprofits, health care providers and government agencies through a customized version of the AHA’s Precision Medicine Platform. An AHA news report has additional information.

Science NewsView All Science News

Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical
09/19/2019 | Many lifesaving oncology drugs may adversely affect the cardiovascular (CV) system, causing irreversible cardiac injury and reduced quali...
ESC Congress 2019 Science News
08/31/2019 | AHA's Science News: Coverage of the European Society of Cardiology Congress 2019 in Paris, France. Aug. 31-Sept. 4, 2019.

Scientific Sessions 2020

Scientific Sessions: Nov. 14–16
 

Dallas, Texas
 

Related Councils

Council on Clinical Cardiology (CLCD)

Eldrin Lewis, MD, MPH, FAHA, FACC

The purpose of the Council on Clinical Cardiology (CLCD) is to achieve the objectives of the American Heart Association (AHA) in the field of clinical cardiology, to promote excellence in clinical care and to foster the professional development and education of clinical cardiologists. Through council-sponsored symposia, panels and scientific conferences, members can access new developments in the field and interpret and promote clinical cardiology to professional and lay audiences.

Eldrin Lewis, MD, MPH, FAHA, FACC
Chair, Council on Clinical Cardiology

Scientific Sessions       Circulation       CLCD Council Awards

Council on Genomic and Precision Medicine (GPM)

Thomas J. Wang, MD, FAHA

The mission of the American Heart Association Council on Genomic and Precision Medicine (GPM) is to advance the discovery and translation of biological insights gained from genetics and omics technologies to improve cardiovascular and brain health. Our constituency’s expertise spans across genetics, genomics, epigenetics, transcriptomics, metabolomics, proteomics, microbiome, bioinformatics, computational science, population health, clinical genetics and genomic medicine, with the ultimate goal of more precise risk prediction, treatment and prevention for patients and the population. Integral to the American Heart Association’s goals, the GPM Council provides a premier inter-disciplinary forum promoting and integrating new knowledge from molecules to populations in translational cardiovascular science and precision medicine.

Thomas J. Wang, MD, FAHA
Chair, Council on Genomic and Precision Medicine

Scientific Sessions       Circulation: Genomic and Precision Medicine      GPM Council Awards
 

AHA / ASA Professional Members are Difference Makers.